Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Pancreatic Cancer Battle Boosted by $200M VC Firm

PR Newswire - Tue Sep 19, 2023

FN Media Group Presents USA News Group News Commentary

VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- USA News Group  -  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MITMemorial Sloan Kettering Cancer Center and The Rockefeller University. Led by 31-year old Reed Jobs, the new firm dubbed 'Yosemite' appears to be an extension of the legacy left by the founder's father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56. From an investment standpoint, the Global Pancreatic Cancer Market is expected to surpass US$7.4 billion by 2032, growing at a health CAGR of 13.7% along the way. Among the biotech sector's most promising developers of treatments for pancreatic cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ:INCY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and BioNTech SE (NASDAQ:BNTX).

Read more at prnewswire.com